This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endologix Announces Preliminary Second Quarter 2013 Revenue Growth Of 33% And Update To Ventana Program

Raises Full Year 2013 Revenue Guidance Conference Call Scheduled for Today, July 1, at 9:00 a.m. ET

IRVINE, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today preliminary unaudited revenue for the second quarter ended June 30, 2013. Endologix anticipates second quarter 2013 global revenue of approximately $34.0 million, representing approximately 33% growth as compared to the second quarter of 2012 and 14% growth as compared to the first quarter of 2013.

The Company anticipates U.S. revenue to be approximately $26.3 million in the second quarter 2013, representing approximately 23% growth compared to $21.4 million for the same quarter in 2012. International revenue is anticipated to be approximately $7.6 million in the second quarter 2013, representing approximately 81% growth compared to $4.2 million for the same quarter in 2012.

John McDermott, Endologix Chairman, President and Chief Executive Officer, said, "We achieved strong sales growth during the second quarter, as a result of the excellent outcomes achieved by physicians with the AFX® Endovascular AAA System and the support provided by our sales and clinical people. Accordingly, we have raised our revenue guidance for the year and remain confident in our long-term outlook for sales growth of approximately 20% or greater year-over-year over the next several years."

Ventana Fenestrated System Program Update

On April 30, 2013, Endologix announced plans to temporarily suspend enrollment in its Ventana U.S. IDE clinical trial and delay the limited market introduction of Ventana in Europe in order to evaluate a higher than expected number of re-interventions. The Company has completed this initial evaluation and has identified training and design enhancements that are expected to reduce the re-intervention rate and improve clinical outcomes. In order to validate these design enhancements, the Company will conduct testing and meet with regulatory agencies to determine the requirements and commercialization timelines. Accordingly, the Company does not anticipate that it will restart enrollment in the Ventana U.S. IDE clinical trial or begin the limited market introduction of Ventana in Europe before the end of the year.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs